Search research articles
Contact Us
Filters
Showing results (61-70 of 748) with videos related to
Page
of 75
Sort By:
Alimentary Pharmacology & Therapeutics
|
July 15, 2023
Editorial: Will MRI-PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply
Daniel Q Huang, Rohit Loomba
The American Journal of Gastroenterology
|
June 4, 2024
Response to Tapper and Chhatwal
Gauree G Konijeti, Rohit Loomba
Hepatology (Baltimore, Md.)
|
September 18, 2025
Reply: Screening and risk stratification disparities in Hispanic MASLD
Monica A Tincopa, Rohit Loomba
Hepatology (Baltimore, Md.)
|
December 6, 2018
Refining Noninvasive Diagnostics In Nonalcoholic Fatty Liver Disease: Closing the Gap to Detect Advanced Fibrosis
Jörn M Schattenberg, Rohit Loomba
Gut
|
February 19, 2020
Advances in non-invasive assessment of hepatic fibrosis
Rohit Loomba, Leon A Adams
Infectious Disorders Drug Targets
|
March 12, 2009
Drug targets in hepatitis B virus infection
Lance L Stein, Rohit Loomba
Alimentary Pharmacology & Therapeutics
|
April 16, 2022
Editorial: screening for hepatocellular carcinoma in NAFLD cirrhosis-towards abbreviated MRI alternative in patients with obesity? Authors' reply
Daniel Q Huang, Rohit Loomba
Journal of Hepatology
|
September 25, 2016
Non-invasive estimation of HVPG by combined structural and hemodynamic evaluation of portal hypertension using quantitative magnetic resonance imaging
Sudhakar Kundapur Venkatesh, Rohit Loomba
Alimentary Pharmacology & Therapeutics
|
December 28, 2023
Letter: Are we forgetting the importance of steatosis in steatotic liver disease? Authors' reply
Selena Z Kuo, Rohit Loomba
Gastroenterology
|
February 22, 2017
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
Rohit Loomba, T Jake Liang
Page
of 75
Search research articles
Search
Showing results (61-70 of 748) with videos related to
Sort By:
Page
of 75
Alimentary Pharmacology & Therapeutics
|
July 15, 2023
Editorial: Will MRI-PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply
Daniel Q Huang, Rohit Loomba
The American Journal of Gastroenterology
|
June 4, 2024
Response to Tapper and Chhatwal
Gauree G Konijeti, Rohit Loomba
Hepatology (Baltimore, Md.)
|
September 18, 2025
Reply: Screening and risk stratification disparities in Hispanic MASLD
Monica A Tincopa, Rohit Loomba
Hepatology (Baltimore, Md.)
|
December 6, 2018
Refining Noninvasive Diagnostics In Nonalcoholic Fatty Liver Disease: Closing the Gap to Detect Advanced Fibrosis
Jörn M Schattenberg, Rohit Loomba
Gut
|
February 19, 2020
Advances in non-invasive assessment of hepatic fibrosis
Rohit Loomba, Leon A Adams
Infectious Disorders Drug Targets
|
March 12, 2009
Drug targets in hepatitis B virus infection
Lance L Stein, Rohit Loomba
Alimentary Pharmacology & Therapeutics
|
April 16, 2022
Editorial: screening for hepatocellular carcinoma in NAFLD cirrhosis-towards abbreviated MRI alternative in patients with obesity? Authors' reply
Daniel Q Huang, Rohit Loomba
Journal of Hepatology
|
September 25, 2016
Non-invasive estimation of HVPG by combined structural and hemodynamic evaluation of portal hypertension using quantitative magnetic resonance imaging
Sudhakar Kundapur Venkatesh, Rohit Loomba
Alimentary Pharmacology & Therapeutics
|
December 28, 2023
Letter: Are we forgetting the importance of steatosis in steatotic liver disease? Authors' reply
Selena Z Kuo, Rohit Loomba
Gastroenterology
|
February 22, 2017
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
Rohit Loomba, T Jake Liang
Page
of 75